Head to Head Contrast: Aktis Oncology (NASDAQ:AKTS) & Zealand Pharma A/S (OTCMKTS:ZLDPF)

Zealand Pharma A/S (OTCMKTS:ZLDPF) and Aktis Oncology (NASDAQ:AKTS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Valuation and Earnings

This table compares Zealand Pharma A/S and Aktis Oncology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zealand Pharma A/S	$1.40 billion	1.82	$977.29 million	$6.03	5.89
Aktis Oncology	$6.50 million	134.62	-$63.73 million	($0.82)	-19.85

Zealand Pharma A/S has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

28.8% of Aktis Oncology shares are held by institutional investors. 3.3% of Aktis Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Zealand Pharma A/S and Aktis Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zealand Pharma A/S	58.86%	17.56%	16.17%
Aktis Oncology	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Zealand Pharma A/S and Aktis Oncology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zealand Pharma A/S	0	9	1	1	2.27
Aktis Oncology	1	0	9	1	2.91

Aktis Oncology has a consensus target price of $35.62, suggesting a potential upside of 118.83%. Given Aktis Oncology’s stronger consensus rating and higher probable upside, analysts plainly believe Aktis Oncology is more favorable than Zealand Pharma A/S.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.